SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02709018

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Enhancing Fear Extinction Via Angiotensin Type 1 Receptor Inhibition: A Randomized Controlled Trial in Posttraumatic Stress Disorder

This study is being conducted to determine if losartan, an angiotensin receptor blocker (ARB), is safe and effective in the treatment of posttraumatic stress disorder (PTSD) symptoms. The study is also intended to determine if certain genetic markers are useful in predicting PTSD symptom reduction with losartan. Approximately 160 subjects with chronic PTSD ages 18-65 will participate in this study across five sites. Subjects will be assigned by chance to take either flexibly dosed losartan (up to a maximum dosage of 100 mg) or placebo (which resembles the study drug but has no active ingredients), once a day for 10 weeks. Furthermore, it is hypothesized that CC homozygotes for rs4311 SNP in the ACE gene will have a superior response to losartan on PTSD symptoms compared to T carriers.

NCT02709018 Posttraumatic Stress Disorder
MeSH: Disease Stress Disorders, Traumatic Stress Disorders, Post-Traumatic

2 Interventions

Name: losartan

Description: Angiotensin receptor blocker (ARB)

Type: Drug

Losartan

Name: Placebo

Description: Placebo

Type: Drug

Placebo


Primary Outcomes

Description: Clinician-Administered PTSD Scale for DSM-5 also known as CAPS 5 is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to, make current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD and assess PTSD symptoms over the past week

Measure: The primary outcome for this study is mean change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) over the treatment period of 10 weeks between the losartan arm and the placebo arm.

Time: 10 weeks

Secondary Outcomes

Measure: Change in CAPS-5 associated with CC homozygosity for rs4311 SNP in the angiotensin converting enzyme gene (ACE) compared to T carriers, among subjects randomized to losartan.

Time: 10 weeks

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 rs4311

Furthermore, it is hypothesized that CC homozygotes for rs4311 SNP in the ACE gene will have a superior response to losartan on PTSD symptoms compared to T carriers.

Change in CAPS-5 associated with CC homozygosity for rs4311 SNP in the angiotensin converting enzyme gene (ACE) compared to T carriers, among subjects randomized to losartan.. null.



HPO Nodes